PUMA BIOTECHNOLOGY, INC.

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative products to improve cancer care and patient treatment outcomes. The company currently commercializes NERLYNX, an oral form of neratinib, which is used to treat certain HER2-positive breast cancers. Puma Biotechnology has also in-licensed alisertib, for which it is responsible for global development and commercialization. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A, designed to disrupt cell division and lead to the death of rapidly growing tumor cells that rely on Aurora Kinase A. Before Puma Biotechnology licensed alisertib from a Takeda Pharmaceutical Company Limited subsidiary, it was tested in over 1,300 patients across 22 company-sponsored trials, creating a large clinical safety database. Based on this data, Puma Biotechnology believes alisertib could be used to treat various cancer types, including hormone receptor-positive breast cancer, triple negative breast cancer, and small cell lung cancer. The company plans to initially develop alisertib for small cell lung cancer and hormone receptor-positive breast cancer.